Endocrinologia Clínica (Lúcio Vilar) - 6 Edição_Parte160

Prévia do material em texto

103.
104.
105.
106.
107.
108.
109.
96:1992-2003.
Katznelson L, Atkinson JL, Cook DM et al. American Association of Clinical Endocrinologists medical guidelines for
clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract. 2011; 17 Suppl 4:1-44.
Minniti G, Gilbert DC, Brada M. Modern techniques for pituitary radiotherapy. Rev Endocr Metab Disord. 2009; 10:135-
44.
Minniti G, Traish D, Ashley S et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary
adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005; 90:800-4.
Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends
Endocrinol Metab. 2013; 24:238-46.
Kasuki L, Vieira Neto L, Wildemberg et al. AIP expression in sporadic somatotropinomas is a predictor of the response to
octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012; 19:L25-9.
Kasuki L, Wildemberg LE, Neto LV et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of
SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol. 2013; 169:217-23.
Gadelha MR. A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized
therapeutic decision-making process. Clin Endocrinol (Oxf). 2015; 83:1-2.
	Endocrinologia Clínica (Lúcio Vilar) - 6ª Edição